The JDF serves as a baseline deployment formulary to treat the most common wounds or diseases that may affect U.S. Armed Forces members. Through its inclusion on the JDF, OFIRMEV is now available for use in deployed theaters by all four U.S. military service branches.
June 8, 2011
Do you like this?
Cadence Pharmaceuticals, Inc.’s OFIRMEV® (acetaminophen) injection has been added to the U.S. Department of Defense's Joint Deployment Formulary (JDF), the core list of pharmaceutical products required for theater-level care of deployed forces. The U.S. Food and Drug Administration (FDA) approved OFIRMEV for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics (pain relievers) and the reduction of fever.
June 8, 2011
All comments are moderated and generally will be posted if they are on-topic and not abusive.
-
Business & Career
ASHP 2012 Summer Meeting & Exhibition-
-
Business & Career
2012 FALL Hospital Pharmacy Conference-
Latest Comments